In 2012, Edwards Lifesciences acquired BMEYE to advance the Nexfin technology into the ClearSight system, the next generation in noninvasive hemodynamic monitoring for continuous decision support.
ClearSight system:
The next generation of Nexfin technology
Important safety information
Important safety information
CAUTION: Federal (United States) law restricts this device to sale by or on the order of a physician.
See Instructions For Use (IFU) / Directions For Use (DFU) for full prescribing information, including indications, contraindications, warnings, precautions and adverse events.